Evidence map›Paper›PMID 27834817›Full record

ArticleInternational journal of molecular sciences2016

Classification of 27 Tumor-Associated Antigens by Histochemical Analysis of 36 Freshly Resected Lung Cancer Tissues.

Gene Kurosawa, Mototaka Sugiura, Yoshinobu Hattori, Hiroyuki Tsuda, Yoshikazu Kurosawa

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Gene KurosawaDivision of Antibody Project, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake 470-1192, Japan. gene@fujita-hu.ac.jp.
Mototaka SugiuraInternal Medicine, School of Medicine, Fujita Health University, Toyoake 470-1192, Japan. msugiura@fujita-hu.ac.jp.
Yoshinobu HattoriDivision of Thoracic and Cardiovascular Surgery, School of Medicine, Fujita Health University, Toyoake 470-1192, Japan. y-hattori@daidohp.or.jp.
Hiroyuki TsudaDepartment of Toxicology, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8603, Japan. htsuda@phar.nagoya-cu.ac.jp.
Yoshikazu KurosawaDivision of Antibody Project, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake 470-1192, Japan. kurosawa@fujita-hu.ac.jp.
Fujita Health University · JPNagoya City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In previous studies, we identified 29 tumor-associated antigens (TAAs) and isolated 488 human monoclonal antibodies (mAbs) that specifically bind to one of the 29 TAAs. In the present study, we performed histochemical analysis of 36 freshly resected lung cancer tissues by using 60 mAbs against 27 TAAs. Comparison of the staining patterns of tumor cells, bronchial epithelial cells, and normal pulmonary alveolus cells and interalveolar septum allowed us to determine the type and location of cells that express target molecules, as well as the degree of expression. The patterns were classified into 7 categories. While multiple Abs were used against certain TAAs, the differences observed among them should be derived from differences in the binding activity and/or the epitope. Thus, such data indicate the versatility of respective clones as anti-cancer drugs. Although the information obtained was limited to the lung and bronchial tube, bronchial epithelial cells represent normal growing cells, and therefore, the data are informative. The results indicate that 9 of the 27 TAAs are suitable targets for therapeutic Abs. These 9 Ags include EGFR, HER2, TfR, and integrin α6β4. Based on our findings, a pharmaceutical company has started to develop anti-cancer drugs by using Abs to TfR and integrin α6β4. HGFR, PTP-LAR, CD147, CDCP1, and integrin αvβ3 are also appropriate targets for therapeutic purposes.

Indexed as

Antibodies, MonoclonalAntigens, NeoplasmAntineoplastic AgentsBronchiEpithelial CellsEpitopesErb-b2 Receptor Tyrosine KinasesErbB ReceptorsGene ExpressionHumansIntegrin alpha6beta4Lung NeoplasmsMolecular Targeted TherapyPeptide LibraryReceptors, TransferrinAntibodies, MonoclonalAntigens, NeoplasmAntineoplastic AgentsEGFR protein, humanEpitopesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsIntegrin alpha6beta4Peptide LibraryReceptors, Transferrincancer-associated antigenscombination therapyhistochemical analysisphage-display antibody librarytherapeutic antibody

Identifiers

PMID27834817
PMCPMC5133862
OpenAlexW2557033467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.